

Friday, 24 September 2021

Scientific Business Meeting (open to the working party members only)

09:00 – 09:45	Welcome	Ibrahim Yakoub-Agha
09:45 – 10:00	Introduction	Patrick Hayden
10:00 – 13:00	SESSION I	
10:00 – 11:10	Plasma cell disorders subcommittee projects presentation	Stefan Schoenland – Meral Beksac
11:10 – 12:20	PH-negative myeloproliferative syndromes subcommittee projects presentation	Donal McLornan – Tomasz Czerw – Juan Carlos Hernandez Boluda
12:20 – 13:00	Chronic myeloid leukemia subcommittee projects presentation	Yves Chalandon
13:00 – 14:00	Lunch break	
14:00 – 17:00	SESSION II	
14:00 – 15:00	Myelodysplastic syndromes including CMML subcommittee projects presentation	Marie Robin – Francesco Onida – Christof Scheid
15:00 – 15:30	Chronic lymphoid leukemia subcommittee projects presentation	Oliver Tournilhac – Michael van Gelder
15:30 – 15:45	Implication of nurses in CMWP scientific life	Maike de Ruijter
15:45 – 16:00	An update on EBMT registry	Johannes Schetelig
16:00 – 16:30	Practice harmonisation and guidelines subcommittee	Patrick Hayden – Laureent Garderet
16:30 – 17:00	Round Table	

Saturday, 25 September 2021

09:00 – 10:20	SESSION III: Myelofibrosis	Chair: Tomasz Czerw
09:00 – 09:15	Introduction	
09:20 – 09:40	How to manage cytopenias post-allo-HCT in MF patients	Donal McLornan
09:40 – 10:00	Allo-HCT in systemic aggressive mastocytosis	Gandhi Damaj
10:00 – 10:20	Round Table	Donal McLornan - Gandhi Damaj – Ibrahim Yakoub-Agha - Juan Carlos Hernandez Boluda
10:20 – 11:20	SESSION IV: Multiple myeloma	Chair: Meral Beksac
10:20 – 10:40	Best regimen to treat relapse after auto-HCT in MM	Xavier Leleu
10:40 – 11:00	CARAMBA academic anti-SLAMF7 CAR T cells	Sara Mastaglio
11:00 – 11:20	Round Table	Xavier Leleu - Sara Mastaglio - Stefan Schoenland - Laureent Garderet
11:20 – 11:30	Break	
11:30 – 12:50	SESSION V: Myelodysplastic Syndrome	Chair: Marie Robin
11:30 – 11:45	Allo-HCT in CMML vs MDS	Alicia Rovo
11:45 – 12:00	Transplant vs no transplant in CMML	Marie Robin
12:00 – 12:15	International Consensus on Allo-HCT in CMML patients	Francesco Onida
12:15 – 12:30	Therapy-related myeloid neoplasm following breast cancer	Mitja Nabergoj
12:30 – 12:50	Round table	Marie Robin – Francesco Onida – Christof Scheid - Mitja Nabergoj
13:35 – 14:10	Lunch break	
14:10 – 15:10	SESSION VI: Session on Statistical Analysis - From standard to current PFS and similar endpoints: approaches and issues	
14:10 – 14:25	Concepts	Liesbeth de Wreede – Simona Iacobelli
14:25 – 14:40	Methods	Liesbeth de Wreede
14:40 – 14:55	Data	Luuk Gras – Linda Koster – Dirk-Jan Eikema
14:55 – 15:10	Round table	
15:10 – 16:30	SESSION VII: Practice harmonisation and guidelines	Chair: Michael van Gelder
15:10 – 15:30	EBMT/EHA best practice guidelines for CAR T-cell patients	Claire Roddie
15:30 – 15:50	Management of CRS/MAS/ICANS	Ibrahim Yakoub-Agha
15:50 – 16:10	Academic production, perspectives and limitation	Chiara Bonini
16:10 – 16:30	Round table	Claire Roddie - Ibrahim Yakoub-Agha - Chiara Bonini - Maaïke de Ruijter – Patrick Hayden
16:30 – 16:50	Break	
16:50 – 17:45	Keynote Lecture	Chair: Yves Chalandon
16:50 – 17:20	Personalized Prognostic Assessment on the basis of clinical and genomic features in MDS	Matteo Della Porta
17:20 – 17:30	Round table	Olivier Tournilhac
17:30 – 17:35	Conclusion	Francesco Onida – Patrick Hayden
		Ibrahim Yakoub-Agha